Damage to liver cells caused by an excess build up of fat in the liver can be mitigated by inhibiting a specific immune system receptor. Scientists described this finding through the press service of the Russian Federation Ministry of Education and Science, highlighting a potential path to protect liver cells from fat-induced harm.
Liver steatosis, or fatty liver, is a risky condition that arises when fat, reactive oxygen species, fatty acids, and other harmful compounds accumulate inside liver cells. This buildup can damage DNA, disrupt other essential molecules, and compromise cell membranes. Mitochondria, the cellular power plants, respond by processing damaged molecules, yet their performance in the liver relies on interleukin-6 (IL-6). In several disease states, the inflammatory gp130 receptor linked to IL-6 becomes activated. Researchers from Immanuel Kant Baltic Federal University in Kaliningrad have shown that blocking this receptor can nearly eliminate fat-related liver cell death in experimental models of obesity, suggesting a new therapeutic angle for liver health in obesity. They point out that gp130 helps liver cells maintain the right balance and health of mitochondria, which are crucial for cell vitality and energy management. This insight could steer the development of drugs aimed at improving liver function in people dealing with obesity and related metabolic stress, offering a tangible step forward in managing fatty liver disease.[Source: Immanuel Kant Baltic Federal University, Kaliningrad]
In one set of laboratory experiments, scientists simulated obesity-related stress in liver cells by introducing a fatty acid solution to cultured hepatocytes. After 24 hours, a noticeable increase in cell death occurred in the fatty-acid-exposed cultures, while untreated control cultures maintained high viability. When researchers added interleukin-6 alongside fatty acids, the damage was reduced and survival improved. The most striking effect emerged when the treatment also included a substance that blocks gp130 receptors; under these conditions, nearly all liver cells remained viable, approaching a hostile-free environment for cellular life. These observations support the idea that IL-6 and gp130 signaling play pivotal roles in how liver cells respond to lipotoxic stress and mitochondrial strain, and that targeted manipulation of this axis can preserve liver cell integrity under metabolic pressure. [Source: Immanuel Kant Baltic Federal University deposition of findings]
The team emphasizes that their findings could accelerate the search for new pharmacological approaches to liver disease associated with obesity. By preserving mitochondrial function and preventing hepatocyte death, potential therapies could reduce liver inflammation and fibrosis that accompany fatty liver conditions. While the work is at an early stage, it provides a clear experimental framework showing how modulating gp130 signaling and IL-6 activity might be harnessed to protect liver tissue in patients with obesity, offering a hopeful direction for future clinical investigations and drug development efforts. [Source: Institute summaries from Kaliningrad researchers]
The researchers also note that the interplay among IL-6, gp130, and mitochondria appears to be context-dependent, meaning that careful dosing and timing will be essential in translating these results into safe, effective therapies. They advocate for further studies to verify these effects in living organisms and to determine whether similar protective mechanisms exist in human liver tissue under metabolic stress. If confirmed, these insights could guide the design of selective inhibitors or modulators that minimize liver damage while preserving normal immune signaling, ultimately contributing to better management of obesity-related liver disease on a broader scale.[Source: Academic briefings from the Baltic Federal University team]
previous experiment showedThe disappearing balloon trick can’t fool the monkeys.
Related posts:
Dietary fat quality and NAFLD risk: fatty fish vs lean fish Klebsiella pneumoniae and Fatty Liver Disease: Gut Microbes as a Factor in NAFLD Sex Differences in Fatty Liver Mortality and the Impact of Alcohol NOX4 in Fatty Liver Disease: Potential Therapies and Implications Eye-based liver cell monitoring offers real-time insights into hepatic health NAFLD, Fibrosis, and Reduced Lung Capacity: New Insights Fatty Liver Disease: Key Causes, Risks, and Management Beta Cells and Mitochondria: A New Diabetes Angle Reframing Liver Health: Myths, Facts, and Practical Guidance {“title”:”Retatrutide Shows Weight Loss and Liver Fat Reduction in Obesity Trials”} Omega-3s May Guard the Liver Against NASH, Oregon State Study Finds NAFLD and the Urea Cycle: New Clues for Treatment